In their study, Feng and colleagues provided evidence that ACSL4, an enzyme that activates ferroptosis, can amplifie the ferroptosis induced by sorafenib and effectively forecasts the sensitivity of HCC to sorafenib (233). This evidence concerns the gene ACSL4 and hepatocellular carcinoma.